UY35037A - ANTIPARASITARY COMPOSITION OF SPACIOUS NITAZOXANIDA SPECTRUM, PROBIOTICS AND PREBIOTICS - Google Patents

ANTIPARASITARY COMPOSITION OF SPACIOUS NITAZOXANIDA SPECTRUM, PROBIOTICS AND PREBIOTICS

Info

Publication number
UY35037A
UY35037A UY0001035037A UY35037A UY35037A UY 35037 A UY35037 A UY 35037A UY 0001035037 A UY0001035037 A UY 0001035037A UY 35037 A UY35037 A UY 35037A UY 35037 A UY35037 A UY 35037A
Authority
UY
Uruguay
Prior art keywords
effective amount
therapeutically effective
composition
nitazoxanida
antiparasitary
Prior art date
Application number
UY0001035037A
Other languages
Spanish (es)
Inventor
Esteban Alejandro Fiore
Original Assignee
Rhein Siegfried Sa De Cv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhein Siegfried Sa De Cv filed Critical Rhein Siegfried Sa De Cv
Publication of UY35037A publication Critical patent/UY35037A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016Disaccharides, e.g. lactose, lactulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/719Pullulans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732Pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733Fructosans, e.g. inulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere una composición farmacéutica, preferentemente oral, utilizada como antiparasitaria y antidiarreica que comprende una cantidad terapéuticamente efectiva del compuesto Nitazoxanida y una cantidad terapéuticamente efectiva de un Probiótico junto a excipientes farmacéut icamente aceptables; y opcionalmente, una cantidad terapéuticamente efectiva de un Prebiótico. Adicionalmente, la presente invención describe usos médicos y métodos para preparar una composición farm acéutica utilizada como antiparasitaria y antidiarreica que comprende una cantidad terapéuticamente efectiva del compuesto Nitazoxanida y una cantidad terapéuticamente efectiva de un Probiótico junto a excipientes farmacéuticamente aceptables, y opcionalmente, una cantidad terapéuticamente efectiva de un Prebiótico.The present invention relates to a pharmaceutical composition, preferably oral, used as an antiparasitic and antidiarrheal comprising a therapeutically effective amount of the Nitazoxanide compound and a therapeutically effective amount of a Probiotic together with pharmaceutically acceptable excipients; and optionally, a therapeutically effective amount of a Prebiotic. Additionally, the present invention describes medical uses and methods for preparing an acetic farm composition used as an antiparasitic and antidiarrheal comprising a therapeutically effective amount of the Nitazoxanide compound and a therapeutically effective amount of a Probiotic together with pharmaceutically acceptable excipients, and optionally, a therapeutically amount. Effective of a Prebiotic.

UY0001035037A 2012-11-13 2013-09-17 ANTIPARASITARY COMPOSITION OF SPACIOUS NITAZOXANIDA SPECTRUM, PROBIOTICS AND PREBIOTICS UY35037A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2012013178A MX2012013178A (en) 2012-11-13 2012-11-13 Broad-spectrum anti-parasitic composition consisting of nitazoxanide, probiotics and prebiotics.

Publications (1)

Publication Number Publication Date
UY35037A true UY35037A (en) 2014-05-30

Family

ID=50730662

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035037A UY35037A (en) 2012-11-13 2013-09-17 ANTIPARASITARY COMPOSITION OF SPACIOUS NITAZOXANIDA SPECTRUM, PROBIOTICS AND PREBIOTICS

Country Status (5)

Country Link
AR (1) AR093252A1 (en)
BR (1) BR112015010651A2 (en)
MX (1) MX2012013178A (en)
UY (1) UY35037A (en)
WO (1) WO2014076638A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108085265B (en) * 2016-11-22 2021-09-28 北京大北农科技集团股份有限公司 Bacillus coagulans new strain, and microecological preparation and feed thereof
GB201708932D0 (en) * 2017-06-05 2017-07-19 Probi Ab Microbial compositions
CN110279118B (en) * 2019-06-14 2022-09-13 浙江大学宁波理工学院 Composite probiotic composition, composite probiotic freeze-dried powder capsule and preparation method

Also Published As

Publication number Publication date
AR093252A1 (en) 2015-05-27
BR112015010651A2 (en) 2017-07-11
WO2014076638A1 (en) 2014-05-22
MX2012013178A (en) 2014-05-22

Similar Documents

Publication Publication Date Title
MX2021000550A (en) Tofacitinib oral sustained release dosage forms.
ECSP14030098A (en) CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
NZ702663A (en) Nuclear transport modulators and uses thereof
EP3904502A3 (en) Compositions and methods
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
AR091006A1 (en) PROLIPOSOMAL TESTOSTERONE FORMULATIONS
MY165888A (en) Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation
TN2015000135A1 (en) Modified release formulations for oprozomib
MX344846B (en) Combination of active loaded granules with additional actives.
BR112014009580A2 (en) omeprazole pharmaceutical composition
MX2016006087A (en) Rapidly disintegrating formulations and methods of use.
UY35037A (en) ANTIPARASITARY COMPOSITION OF SPACIOUS NITAZOXANIDA SPECTRUM, PROBIOTICS AND PREBIOTICS
IN2015DN02999A (en)
MX359887B (en) Chewable composition for oral administration and process for preparing thereof.
MX355719B (en) Pharmaceutical composition in the form of an oral suspension including a flavonoid fraction and xanthan gum.
MX2020006075A (en) Bendamustine pharmaceutical compositions.
MX2016011706A (en) Progesterone formulations.
BR112013025610A2 (en) use of a live avian metapneumovirus and pharmaceutical composition
PE20170201A1 (en) PHARMACEUTICAL DOSAGE FORMS
MX2014011922A (en) Composition for the treatment of inflammatory and immune disorders.
BR112014032033A2 (en) formulations for the preparation of oral immediate release tablets containing a low dosage of mifepristone, tablets thereby obtained and their preparation process
IN2013MU01226A (en)
IN2013MU02238A (en)
MX2013003022A (en) Pharmaceutical compositions of montelukast and levocetirizine.
CA2864049A1 (en) Use of beta-nerve growth factor for inducing ovulation in mammals